Collegium Pharmaceutical Inc. (COLL) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (59% profit margin, 85% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-01, Collegium Pharmaceutical Inc. (NASDAQ: COLL) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $24.03 (+3.44% 1D, market cap $782.3M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, COLL ranks #76 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COLL carries a Roarable B (72/100 RQD), trailing P/E of 12.4x, gross margin of 59.3%, and ROIC of 85.0%. By comparison, HELP (Helus Pharma Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $782.5M) and AVBP (ArriVent BioPharma Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $786.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
Per COLL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001267565), Collegium Pharmaceutical Inc. generated $780.6M in revenue (+23.6% YoY), $63.0M in net income, and $327.6M in free cash flow against $1.66B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 42% FCF Margin ($327.6M FCF) & 59.3% Gross Margin
FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 56.9 (BULLISH MOMENTUM)
Balance-sheet & 10-K footnote risk deducts 8 pts from forensic ceiling
Even with a 72/100 (B) score, COLL faces multiple-compression risk if 12.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 56.8% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($23.30) or 200D SMA ($33.24) invalidates the momentum regime and cuts Target Base ($25.54) toward Bear Floor ($19.70).
Collegium Pharmaceutical Inc. (COLL) surged +3.44% to $24.03, trading at 9% of its 52-week range ($21.43 – $50.79). High-quality cash engine (59% profit margin, 85% return on capital) with steady institutional support.
Third Avenue Management, an investment management company, released its third-quarter 2026 investor letter for the “Third Avenue Small-Cap Value Fund”. The letter can be downloaded here. The Third Avenue Small-Cap Value
Third Avenue Management, an investment management company, released its third-quarter 2026 investor letter for the “Third Avenue Small-Cap Value Fund”. The letter can be downloaded here. The Third Avenue Small-Cap Value
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say ni
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families Collegium and Boston Legacy FC in action A partner
HCA's Q3 earnings and revenues beat estimates on higher admissions and ER visits, while rising costs and fewer surgeries temper growth.
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Collegium Pharmaceutical (NASDAQ:COLL) and its peers.
STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood
Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidate) CII in adults and
As previously disclosed, Collegium Pharmaceutical, Inc. (the "Company") is party to a License Agreement (U.S.), dated as of January 13, 2015, with Grünenthal GmbH ("Grünenthal") (as amended, the
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +23.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on COLL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for COLL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Collegium Pharmaceutical Inc. (COLL) ranks #76 by composite RQD confidence (72/100, grade B) and #389 by equity capitalization ($782.3M). Within this direct 5-issuer industry benchmark cohort, COLL leads on earnings valuation at 12.4x trailing P/E, while COLL leads on capital efficiency and profitability with 85.0% ROIC and 59.3% gross margin. COLL currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| COLL
ACTIVE
Collegium Pharmaceutical Inc. | B | 72/100 | 12.4x | 59.3% | 85.0% | +3.44% | $782.3M | Benchmark Subject |
| HELP Helus Pharma Inc. | D | 49/100 | — | — | — | -1.83% | $782.5M | /help-vs-coll → |
| AVBP ArriVent BioPharma Inc. | D- | 35/100 | — | — | -35.0% | +1.40% | $786.5M | /avbp-vs-coll → |
| ARDX Ardelyx Inc. | D- | 35/100 | — | 90.3% | -32.7% | 0.00% | $772.5M | /ardx-vs-coll → |
| ANNX Annexon Inc. | D- | 40/100 | — | — | -35.0% | -0.74% | $760.2M | /annx-vs-coll → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Collegium Pharmaceutical Inc. (COLL) reported GAAP revenue of $780.6M (+23.6% vs. FY2024 revenue of $631.4M , and +37.7% cumulative change since FY2023) , GAAP net income of $63.0M, operating cash flow of $329.3M, and free cash flow of $327.6M (+61.1% YoY). On the balance sheet, COLL closed FY2025 with $1.66B in total assets against $0 in total debt (Altman Z-Score: 1.27, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $780.6M | $63.0M | $329.3M | $327.6M | $1.66B | — |
| FY2024 (FY) | 2024-12-31 | $631.4M | $69.0M | $205.0M | $203.3M | $1.66B | — |
| FY2023 (FY) | 2023-12-31 | $566.8M | $48.0M | $274.7M | $274.7M | — | — |
As of 2026-11-01, Collegium Pharmaceutical Inc. (NASDAQ: COLL) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $24.03 (+3.44% 1D, market cap $782.3M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, COLL ranks #76 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), COLL carries a Roarable B (72/100 RQD), trailing P/E of 12.4x, gross margin of 59.3%, and ROIC of 85.0%. By comparison, HELP (Helus Pharma Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $782.5M) and AVBP (ArriVent BioPharma Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $786.5M). Among the 5-stock peer group, COLL leads on earnings multiple (12.4x) while COLL leads on capital efficiency (85.0% ROIC).
Per COLL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001267565), Collegium Pharmaceutical Inc. generated $780.6M in revenue (+23.6% YoY), $63.0M in net income, and $327.6M in free cash flow against $1.66B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (59% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
COLL last traded at $24.03 (+3.44% on volume of 656,483 shares), positioning the stock +3.13% above its 50-day simple moving average ($23.30) and -27.71% below its 200-day simple moving average ($33.24). Across its 52-week range of $21.43 to $50.79, COLL sits at the 8.9% percentile with a 14-day RSI of 56.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.9% ($22.37 to $25.69).
Why COLL Stock surged +3.44% Today — RQD Quant Desk Flash. High-quality cash engine (59% profit margin, 85% return on capital) with steady institutional support.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.